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Background: Chronic mountain sickness (CMS), originally characterized by excess hemoglobin (Hb), is currently
diagnosed using score-based diagnostic criteria combined with excessive erythrocytosis and clinical symptoms.
However, the current criteria have limited applicability. We applied these criteria to 1,029 Chinese Han males
migrated to and have been stayed at the Qinghai-Tibet plateau (3,700–5,000 m) for 2–96 months to investigate the
prevalence of CMS and its correlations with Hb concentration, altitude, and the length of residence.
Methods: Subjects were screened for CMS using the latest approved diagnostic criteria combined with excessive
erythrocytosis and clinical symptoms. Hb concentrations were measured, and a cut-off point was determined with
k-means clustering. Predisposing factors were evaluated with binary logistic analysis and curve fitting analysis.
Results: (1) The prevalence of CMS at the Qinghai-Tibetan plateau was 17.8% (183/1029 subjects, with CMS
score ≥ 6, and Hb ≥ 210 g/L), which is higher than that previously reported. (2) While individuals were identified into
two Hb clusters with a cut-off point of 200 g/L, in the low-Hb cluster (Hb < 200 g/L), the oxygen saturation
remained stable as the Hb increased; in the high-Hb cluster (Hb ≥ 200 g/L), the oxygen saturation decreased as the
Hb increased. (3) Two critical factors associated with CMS development were residence at an altitude of 4,500 m
and a 60-month length of residence.
Conclusions: Our presenting scoring system is more sensitive than previous diagnostic criteria and favors early
screening and treatment of patients with CMS. Our finding suggests that an adjusted Hb threshold of 200 g/L
(instead of 210 g/L) is more adaptable in Han individuals at all altitudes. The weight of Hb level should score ≥ 6
points using the CMS scoring system because of the pathophysiologic role of excessive erythrocytosis in patients
with CMS. In addition, our data suggest the importance of early screening of CMS via regular medical examinations
within the first 60 months of residence at high altitudes, especially >4500 m.
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Chronic mountain sickness (CMS) was first described as
“Monge’s disease” by Carlos Monge in 1928 [1], which is
characterized by excessive erythrocytosis with the typical
symptoms of polycythemia, hypoxemia, breathlessness,
palpitations, sleep disturbances, cyanosis, venous dilata-
tion, headaches, tinnitus, and dizziness [2]. There are ap-
proximately 140 million people living at high altitudes
(>2,500 m) [2] and exposed to the risk of CMS in the
world. In the Qinghai-Tibetan plateau of China where
the largest population lives at a high altitude worldwide,
CMS has been certified as an occupational disease by
the Ministry of Health of People’s Republic of China.
Patients with CMS lose their ability to adapt to hypoxia
and thus are unable to remain stay or full-time work at
high altitudes. Therefore, patients must be precisely di-
agnosed and properly treated as early as possible once
the development of CMS initiated.
However, it has been controversial regarding the def-
inition and diagnostic criteria of CMS during the past
decades. One focus of this debate is the diagnostic set-
ting of hemoglobin (Hb) threshold for polycythemia.
Polycythemia is essentially an adaptive response to long-
term hypoxic exposure, making it difficult to be distin-
guished from a maladaptive response. So far, different Hb
thresholds at high altitudes have been used by medical
researchers from different groups and countries [3-8].
To unify the definition and diagnostic criteria of CMS,
the Sixth World Congress on Mountain Medicine and
High Altitude Physiology redefined CMS as excessive
erythrocytosis (Hb ≥ 190 g/L in female patients; Hb ≥
210 g/L in male patients), severe hypoxemia, and, in some
cases, moderate to severe pulmonary hypertension [9],
and a quantitative CMS diagnostic criterion - the CMS
score, based on symptoms and the Hb concentration,
was also proposed and approved by the International
CMS Consensus Working Group [9].
While the CMS scoring system has been applied in a
small number of studies to date [4-8], improvement and
refinement for the criteria is still needed. For example,
Hb thresholds of 200 g/L [7,8] and 210 g/L [4-6] have
both been used in male patients. Also, with respect to
the essential diagnostic criteria for CMS, whether a sole
excessive Hb level, a sole CMS score of ≥6, or both
should be applied remains confused. For instance, in one
study, subjects were grouped into those with polycy-
themia (with an increased Hb level) and those with a
CMS score of ≥6 [5]. In another study, subjects were
grouped according to CMS scores of ≤4, 5 to 9, or ≥10
[10], which is in contrast to the grouping of ≤5, 6 to 10,
10 to 14, or ≥15 recommended by the Consensus State-
ment [9]. Furthermore, some researchers believe that
most of the CMS symptoms are also commonly shared
with cardiac, pulmonary, and other diseases, which leadthe scoring system less reflect maladaptation to high alti-
tudes after long-term hypoxic exposure, but instead may
reflect lung or cardiac malfunction. Therefore, laboratory
indices, such as the Hb level, oxygen saturation, and
carbon dioxide retention, have been suggested to be more
appropriate for CMS scoring [11].
In the presenting cross sectional study, we investigated
the prevalence of CMS in 1,029 Chinese Han individuals
who migrated to the Qinghai-Tibetan plateau at an alti-
tude of 3,700 to 5,000 m using the latest approved scoring
system. In addition, we analyzed the cut-off point of
Hb for CMS diagnosis using a data mining method and
further discussed the impacts of altitude and length of
residence on the prevalence of CMS.
Methods
Ethics statement
The current survey was approved by the Ethics Review
Board of the Third Military Medical University, Chongqing,
China. Separate written informed consent was obtained
from all subjects. No health interventions involving the
subjects were performed. All individual data were anon-
ymized prior to analysis.
Study population
Men are reportedly more prone to CMS than are women
[12,13]. To exclude a sex difference, we only recruited
men in our study. In total, 1,029 male Han Chinese
volunteers were recruited from the Qinghai-Tibetan
plateau (elevation: 3,700–5,000 m). The study partici-
pants were born and previously lived in low-altitude
areas, including the Anhui, Beijing, Gansu, Guizhou,
Hebei, Henan, Heilongjian, Hubei, Hunan, Jilin, Jiangsu,
Jiangxi, Liaoning, Ningxia, Qinghai, Shandong, Shanxi,
Shaanxi, Sichuan, Xinjiang, and Chongqing provinces of
China. The following basic information about the sub-
jects was obtained using a questionnaire: age (24.08 ±
5.66 years), height (172.11 ± 4.94 cm), and weight (63.72 ±
7.81 kg). All subjects had resided at a high altitude for
2 months–8 years before testing. Individuals with pulmon-
ary or cardiac diseases were excluded. Acute mountain
sickness (AMS) and other disease histories, as well as
cigarette and alcohol use, were also recorded from the
questionnaire. An individual who has consumed at least
100 cigarettes in life was defined a smoker, and who con-
sumes at least 20 g of pure alcohol per day was defined a
drinker.
Measurement of Hb, oxygen saturation, and heart rate
The Hb concentration was determined by cyanide meas-
urement of blood samples obtained from each subject.
Each sample was tested in duplicate. Physical parameters
were recorded in the sitting position between 9:00 am
and 12:00 am. The finger blood oxygen saturation (sO2)
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oximeter (TuffSat; GE Healthcare, London, England).
The heart rate (HR) and pulse pressure were determined
with an electronic sphygmomanometer (HEM-7112;
Omron, Kyoto, Japan).
CMS diagnosis and score calculation
The CMS diagnosis and score calculation were based on
published criteria [9]. Briefly, symptoms of breathlessness/
palpitations, sleep disturbances, cyanosis, venous dilata-
tion, paresthesia, headache, and tinnitus were weighted
(0–3 points) according to severity. The Hb concentra-
tion was weighted (0 or 3 points) with a cut-off of
210 g/L. The points for all symptoms and the Hb con-
centration were summed to yield the CMS score. The
severity of CMS was defined as follows: absent, score of
0 to 5; mild, 6 to 10; moderate, 11 to 14; and severe, ≥15
(the ≥15-point score was based on the Consensus State-
ment). A subject was considered to have CMS only if
the Hb concentration was ≥210 g/L and the CMS score
was ≥6. A subject was considered not to have CMS if
the Hb concentration was <210 g/L or the CMS score
was <6.
Predisposing factors for CMS
Various predisposing factors for CMS have been previ-
ously studied, including altitude, sex, age, ethnicity, length
of residence, geographic factors, and cigarette smoking
[14-16]. Since only Han males residing at the Qinghai-
Tibetan plateau were tested in the current study, thus the
influences of sex, ethnicity, and geographic factors were
exclude. However, the factor of alcohol drinking was not
excluded due to it is commonly performed in Han popula-
tions at high altitudes. To explore possible predictive pa-
rameters for diagnosis, we selected physiological indices,
including the sO2, HR, body mass index (BMI), and mean
blood pressure, which have been proven to be affected
by long-term hypoxic exposure. Because CMS symp-
toms are somewhat nonspecific, we included in the
analysis a history of AMS, arthritis, stomach ulcer-
ation, cough, headache, cervical osteoarthritis, and
other conditions. We pooled all other disease histories
and grouped the subjects for comparison with subjects
with no disease history because the sample number
was not sufficiently large.
Statistical analysis
We compared the CMS prevalences (%) with the χ2 test
and the means of two different groups with the inde-
pendent t-test. Data clusters were determined using the
k-means clustering method. Pearson and Spearman co-
efficients were used to test bivariate correlations. Curve
regression was also performed. The risk of CMS associ-
ated with each characteristic was tested by using a two-sided full model logistic regression analysis. All factors
were firstly tested for bivariate correlations. Because the
age and length of exposure to a high altitude were
strongly correlated (data not shown), we omitted age
and selected the length of exposure to a high altitude
for the analysis. The independent variables which were
entered into the final regression model included: alti-
tude, sO2, drink, mean BP, BMI, altitude time, HR, AMS
history, smoke, and disease history. A p value of <0.05
was considered to be statistically significant.
Results
Prevalence of CMS
Of the 1,029 subjects investigated, 183 (17.8%) were diag-
nosed with CMS, including 101 (9.8%) mild (CMS score
of 6–10), 57 (5.5%) moderate (CMS score of 11–14), and
25 (2.4%) severe cases (CMS score of ≥15). Notably, the
Hb concentrations and CMS symptoms sometimes devi-
ated from each other. Among 782 subjects with low Hb
concentrations (Hb < 210 g/L), 214 had a CMS score of 6
to 10, 36 had a CMS score of 11 to 14, and 11 had a CMS
score of ≥ 15 (Table 1).
Correlations among Hb concentration, sO2, and
symptoms
The Hb concentration was significantly correlated with
the sO2 (Pearson = −0.121, p = 0.000) (Table 2). Curve
fitting analysis demonstrated that the best fitting curve
was a quadratic curve (F = 16.320, p = 0.000) (Table 2),
suggesting a two-phase Hb–sO2 relationship according
to the Hb value. We then classified the Hb concentra-
tion into two clusters using the k-means cluster method.
The first cluster of Hb was 164.0–202.0 g/L (185.57 ±
10.64 g/L; 95% CI, 200.5–203.4 g/L); the second cluster
was 202.3–282.5 g/L (218.68 ± 14.27 g/L; 95% CI, 203.4–
251.3 g/L). Based on the above findings, we used 200 g/L
as the Hb cut-off point and divided the whole cohort into
two clusters: the high Hb cluster (HHbC), comprising
subjects with an Hb concentration of ≥200 g/L, and the
low Hb cluster (LHbC), comprising subjects with an Hb
concentration of <200 g/L. We demonstrated that the
Hb concentration, CMS score, and altitude of residence
were significantly higher in the HHbC than in the LHbC
cluster (p = 0.000, p = 0.000, and p = 0.000, respectively)
(Figure 1E–G).
Next, we determined the correlations among the Hb,
sO2, and total symptom score (CMS score minus Hb
score) in the two Hb clusters. In the HHbC, sO2 was nega-
tively correlated with Hb (Pearson = −0.281, p = 0.000),
while the above two parameters were not significantly
correlated in the LHbC (Pearson = 0.041, p = 0.338)
(Figure 1A); the mean sO2 value was significantly higher
in the LHbC (88.89 ± 8.37%) than in the HHbC (88.40 ±
3.36%, p = 0.036) (Figure 1B). The total symptom score
Table 1 CMS score summary
CMS score
< 6 6-10 11-14 ≥ 15
Prevalences (n = 1029) 585 315 93 36
Percentage 56.85% 30.61% 9.04% 3.50%
Hb Mean ± SD (g/L) 191.00 ± 15.01 199.47 ± 20.22 210.41 ± 22.64 217.81 ± 29.95
Hb range (g/L) 146.0-247.0 153.5-269.0 161.5-282.5 167.5-267.5
Hb (g/L)— no. (%)
< 210 (n = 782) 521 (66.62) 214 (27.37) 36 (4.60) 11 (1.41)
≥ 210 (n = 247) 64 (25.91) 101 (40.89) 57 (23.08) 25 (10.12)
Breathlessness/Palpitations — no. (%)
0 (n = 442) 376 (85.07) 55 (12.44) 10 (2.26) 1 (0.23)
1 (n = 458) 196 (42.79) 211 (46.07) 44 (9.61) 7 (1.53)
2 (n = 114) 13 (11.40) 46 (40.35) 37 (32.46) 18 (15.79)
3 (n = 15) 0 (0.00) 3 (20.00) 2 (13.33) 10 (66.67)
Sleep disturbance— no. (%)
0 (n = 467) 400 (85.65) 56 (11.99) 11 (2.36) 0 (0.00)
1 (n = 361) 150 (41.55) 176 (48.75) 32 (8.86) 3 (0.83)
2 (n = 166) 33 (19.88) 76 (45.78) 39 (23.49) 18 (10.84)
3 (n = 35) 2 (5.71) 7 (20.00) 11 (31.43) 15 (42.86)
Cyanosis— no. (%)
0 (n = 441) 384 (87.07) 54 (12.24) 2 (0.45) 1 (0.23)
1 (n = 347) 159 (45.82) 162 (46.69) 24 (6.92) 2 (0.58)
2 (n = 160) 31 (19.38) 71 (44.38) 46 (28.75) 12 (7.50)
3 (n = 81) 11 (13.58) 28 (34.57) 21 (25.93) 21 (25.93)
Dilatation of veins— no. (%)
0 (n = 793) 548 (69.10) 212 (26.73) 28 (3.53) 5 (0.63)
1 (n = 161) 31 (19.25) 84 (52.17) 38 (23.60) 8 (4.97)
2 (n = 58) 5 (8.62) 15 (25.86) 22 (37.93) 16 (27.59)
3 (n = 17) 1 (5.88) 4 (23.53) 5 (29.41) 7 (41.18)
Paresthesia — no. (%)
0 (n = 518) 446 (86.10) 69 (13.32) 2 (0.39) 1 (0.19)
1 (n = 355) 129 (36.34) 178 (50.14) 44 (12.39) 4 (1.13)
2 (n = 119) 8 (6.72) 58 (48.74) 37 (31.09) 16 (13.45)
3 (n = 37) 2 (5.41) 10 (27.03) 10 (27.03) 15 (40.54)
Headache— no. (%)
0 (n = 435) 382 (87.82) 50 (11.49) 3 (0.69) 0 (0.00)
1 (n = 431) 190 (44.08) 194 (45.01) 44 (10.21) 3 (0.70)
2 (n = 130) 13 (10.00) 65 (50.00) 34 (26.15) 18 (13.85)
3 (n = 33) 0 (0.00) 6 (18.18) 12 (36.36) 15 (45.45)
Tinnitus— no. (%)
0 (n = 596) 482 (80.87) 101 (16.95) 12 (2.01) 1 (0.17)
1 (n = 336) 98 (29.17) 175 (52.08) 55 (16.37) 8 (2.38)
2 (n = 77) 5 (6.49) 33 (42.86) 23 (29.87) 16 (20.78)
3 (n = 20) 0 (0.00) 6 (30.00) 3 (15.00) 11 (55.00)
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Table 2 Correlation analysis model summary and parameter estimates of Hb with sO2
R Square F Sig. Constant b1 b2 b3
Linear 0.015 13.218 0.000 92.878 −0.021
Logarithmic 0.012 10.883 0.001 109.176 −3.880
Inverse 0.010 8.760 0.003 85.163 689.842
Quadratic 0.035 16.320 0.000 59.677 0.308 −0.001
Cubic 0.035 16.300 0.000 71.091 0.141 0.000 −0.000
Compound 0.014 12.787 0.000 92.947 1.000
Power 0.012 10.511 0.001 111.853 −0.044
S 0.009 8.446 0.004 4.444 7.832
Growth 0.014 12.787 0.000 4.532 −0.000
Exponential 0.014 12.787 0.000 92.947 −0.000
Logistic 0.014 12.787 0.000 0.011 1.002
Dependent variable: sO2; The independent variable is Hb.
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(Spearman = 0.144, p = 0.000) (Figure 1C), but not in the
LHbC (Spearman = 0.035, p = 0.993). The total symptom
score was significantly lower in the LHbC than in the
HHbC (p = 0.000) (Figure 1D).
Predisposing factors for CMS
We used binary logistic analysis to investigate CMS risk
factors, including altitude, length of exposure to a high
altitude, cigarette smoking, alcohol drinking, sO2, HR,
BMI, AMS history, other disease history, and mean
blood pressure. The altitude, length of exposure to a
high altitude, sO2, HR, BMI, alcohol consumption, AMS
history, and mean blood pressure were significantly cor-
related with the prevalence of CMS (p = 0.000, p = 0.021,
p = 0.000, p = 0.023, p = 0.001, p = 0.000, p = 0.034, and
p = 0.000, respectively). However, cigarette smoking and
a history of diseases other than AMS were not significant
risk factors for CMS (p = 0.108 and p = 0.909, respectively)
(Table 3). Using these factors, we performed binary logistic
analysis to derive an anticipation equation (Table 4) with
which 93.38% of CMS-vulnerable and 37.60% of nonvul-
nerable persons can be anticipated (Table 5).
Because height and the duration of exposure to a high
altitude were found to be correlated with the CMS score,
we proceeded to cluster these two parameters with the
k-means cluster method and found cut-offs of 4,500 m
and 60 months, respectively. In the cluster of an altitude
of <4500 m, the Hb concentration was not significantly
correlated with the height (F = 0.042, p = 0.836) with a
relatively low mean Hb concentration (192.5 ± 1.72 g/L),
while it was significantly correlated with height (F =
10.936, p = 0.001) in the cluster of an altitude of ≥4500 m
with the mean value exceeded our cut-off point (207.4 ±
21.8 g/L) (Figure 2A,B). In the cluster of an altitude
time of <60 months, the Hb concentration was signifi-
cantly correlated with the length of residence (F = 53.674,p = 0.000) with a low mean value, while it was not signifi-
cantly correlated with the length of residence (F = 0.346,
p = 0.557) in the cluster of an altitude of ≥60 months
with the mean value of >200 g/L (Figure 2C,D). Interest-
ingly, there was a negative correlation between the CMS
score and altitude in the <4500-m cluster (F = 12.361,
p = 0.000) and the mean CMS score remained <6 points.
While the CMS score increased according to the altitude
in the other cluster (F = 10.816, p = 0.001) with a mean
CMS score of about 8 (Figure 2E,F). On the other hand,
the CMS score increased rapidly within 60 months after
ascent to a high altitude (F = 148.883, p = 0.000) and broke
the 6-point threshold after approximately 2 years (y =
0.1137x + 3.0812) (Figure 2G). After 60 months, the mean
CMS score exceeded 8 points and increased rather slowly
as the exposure time was prolonged (F = 7.446, p = 0.007)
(Figure 2G,H).
Discussion
In past decades, thousands of patients with CMS have
been investigated with a focus on the pathophysiologic
mechanisms of this medical condition. Nevertheless, a
number of questions remain to be elucidated. In the
current study, we used the latest diagnostic criteria of
CMS to evaluate 1,029 Chinese Han males who had
been residing at Qinghai-Tibet plateau (3,700–5,000 m)
for 2 months to 8 years. The prevalence of CMS in
above population was 17.8% at 3,700 to 5,000 m, which
is higher than that of previous report with a prevalence
of 11.83% at 4,006 to 5,226 m [17] at the Qinghai-
Tibetan plateau. Our results using the latest diagnostic
criteria suggest that present scoring system is more sen-
sitive than previous diagnosis criteria, and favors early
screening and treatment of patients with CMS. Our data
demonstrate that 200 g/L is the optimal for a cut-off
point of Hb concentration in Han males residing at a
high altitude though a cut-off of Hb concentration
Figure 1 Correlations among Hb, sO2, and symptoms. (A) Curve fitting analysis of Hb concentration and sO2. (B) Mean sO2 in the groups
with an Hb of <200 and ≥200 g/L. (C) Curve fitting analysis of Hb concentration and total symptom score. (D) Total symptom score in the groups with
an Hb of <200 and ≥200 g/L. (E) Hb in the groups with an Hb of <200 and ≥200 g/L. (F) CMS scores in the groups with an Hb of <200 and ≥200 g/L.
(G) Altitude in the groups with an Hb of <200 and ≥200 g/L.
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portant criterion for CMS in the published Consensus
Statement [9]. We found a discrepancy between CMS
symptoms and an excessive Hb level (≥210 g/L) in some
subjects and characterized the effect patterns of height
and length of residence at a high altitude on the Hb
concentration and CMS prevalence.Debate on Hb threshold selection
Several CMS scoring systems have been suggested [18-20]
while the 210 g/L has mainly been used as the diagnostic
criterion for male patients [9]. Previously reported criteria
were most often calculated by the mean Hb concentration
plus 2, 3, or 4 times the standard deviation (SD) of the
entire population [18,21]. A Chinese group selected an
Table 3 Binary logistic correlation analysis of risk factors
for CMS
Score p
Altitude (meters) 38.5872 0.0000
sO2 (%) 25.1352 0.0000
Drink 14.6975 0.0001
Mean BP (mmHg) 13.6726 0.0002
BMI (kg/m2) 11.5360 0.0007
Altitude time (months) 5.2909 0.0214
HR (beat/min) 5.1919 0.0227
AMS history 4.4831 0.0342
Smoke 2.5889 0.1076
Disease history 0.0130 0.9092
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Tibetans living at a high altitude as a reference for im-
migrants [22], designating Tibetans as the best high
altitude-adapted population [23]. An Hb threshold of
200 g/L (mean plus 3 times the SD) has also been pro-
posed [17]. Although calculation of the threshold with
the mean plus a specific multiple of the SD at sea level
is a commonly used method, the Hb concentration in-
creases according to the elevated altitude both physic-
ally and pathologically. Individuals with an excessively
increased Hb concentration could “pollute” the Hb distri-
bution among the whole cohort, resulting in an artificial
threshold derived from the mean and SD in addition to
the subjective selection of the SD. For example, the Hb
concentration was 20.74 ± 2.18 g/dL in men who resided
above 4,500 m, and the threshold point was as high as
25.1 g/dL using the mean plus twice the SD. The Tibetan
threshold is not a good reference because the Tibetans are
resistant to CMS and may not be comparable with the
Hans and other high-altitude populations [24].Table 4 Variables in the CMS anticipation equation
B S.E. Wald p Ex
Altitude 0.0025** 0.0005 20.6871 0.0000 1.
Altitude time 0.0061* 0.0031 3.8763 0.0490 1.
Smoke −0.0600 0.1670 0.1311 0.7172 0.
Drink 1.0292* 0.2601 15.6731 0.0000 2.
sO2 −0.1388** 0.0392 12.5181 0.0004 0.
HR 0.0019 0.0090 0.0426 0.8364 1.
BMI 0.0806 0.0561 2.0610 0.1511 1.
AMS history −0.5221 0.2714 3.7003 0.0544 0.
Disease history −0.3839 0.3877 0.9806 0.3221 0.
Mean BP 0.0214 0.0123 3.0455 0.0810 1.
Constant −4.1097 4.8249 0.7255 0.3943 0.A data-mining analysis technique was introduced in
this study to calculate the Hb threshold based on the
“optimal” Hb concentration concept [25]. When a hu-
man ascends to a high altitude, adaptive reactions begin
to ameliorate hypoxemia owing to the low oxygen partial
pressure of inhaled air. Hypoxemia can upregulate the
transcription factor hypoxia inducible factor-1 and induce
a number of hypoxia-inducible genes, including erythro-
poietin [26]. The release of erythropoietin leads to erythro-
cytosis and an increase in the Hb concentration [27] so
that the blood is able to carry more oxygen to tissues and
cells for utilization. Conversely, excessive erythrocytosis
can also increase blood viscosity and slow blood velocity,
which may decrease the cardiac output [25] and aggravate
arterial hypoxemia, slowing the blood supplication to tis-
sues. This suggests the existence of an “optimal” Hb con-
centration; i.e., when the Hb concentration is below the
“optimal” value, physiologic erythrocytosis response helps
to elevate ability of blood to transport oxygen. When the
Hb exceeds this optimal value, the erythrocytosis response
aggravates the oxygen supplication-demanding imbalance
and triggers CMS pathologic processes.
K-means clustering is a statistical method used to par-
tition observations into clusters with the nearest means,
which serve as prototypes of the clusters. In this study,
we were able to completely separate the subjects into
two populations (Hb of <200 and ≥200 g/L) using k-
means clustering analysis; subsequent analyses showed
that the 95% CIs were clearly nonoverlapping. In this
sense, the nonoverlapping range can serve as a thresh-
old for the different dynamics of the two populations.
When the Hb level drifts beyond the 95% CI, further
drifting away from the first population will lead to
marked changes in the Hb–sO2 relationship. In the first
population (Hb < 200 g/L), which represents the physio-















Table 5 Model detection of the CMS anticipation





CMS 296.0000 21.0000 93.3754 88.3319 0.000
Non-CMS 78.0000 47.0000 37.6000
Overall percentage 77.6018
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which represents the pathologic response part of ery-
throcytosis, the sO2 decreases as the Hb increases. The
correlations between Hb and the symptoms in the two
subpopulations further confirm the marked changes in
the Hb–sO2 relationship. Still, more remains to be elu-
cidated regarding the Hb threshold, such as that inFigure 2 Correlations of Hb, symptom score, and CMS score with alti
analysis of Hb concentration and altitude. (B) Hb concentration in the grou
Hb concentration and length of exposure to high altitude. (D) Hb concent
and ≥60 months. (E) Curve fitting analysis of CMS score and altitude. (F) C
(G) Curve fitting analysis of CMS score and length of exposure to high altit
altitude of <60 and ≥60 months.female individuals and native highlanders, including
Tibetans and Andeans.
Discrepancy between Hb concentration and symptoms
Our data also showed a discrepancy between the Hb
concentration and CMS symptoms. Some subjects had a
very high Hb concentration but could not be classified
as patients with CMS because their CMS symptoms were
obscure. Excessive erythrocytosis per se represents a threat
to humans, sometimes even a lethal threat, because of the
risk of development of a thrombus or embolism in vital
organs [28,29]. If the diagnosis of CMS cannot be made,
dangerous health conditions might be disregarded and
proper medical treatment will not be rendered. Some indi-
viduals with low Hb concentrations and severe CMS
symptoms could not be diagnosed with CMS. Althoughtude and length of residence at high altitude. (A) Curve fitting
ps at an altitude of <4500 and ≥4500 m. (C) Curve fitting analysis of
ration in the groups with a length of exposure to high altitude of <60
MS score in the groups at an altitude of <4500 and ≥4500 m.
ude. (H) CMS score in the groups with a length of exposure to high
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tration and each CMS symptom, all were rather weak with
the exception of cyanosis (data not shown). Therefore,
there may be a low-Hb subtype of CMS that differs from
the present subtype characterized by a high Hb concentra-
tion; i.e., Monge’s disease or polycythemia. In the high-Hb
subtype, excessive erythrocytosis is the primary risk factor;
in the low-Hb subtype, other risk factors such as long-
term insufficient oxygen supplication to vital organs are
likely to be fundamental causes [30].
CMS was first termed “erythema syndrome of high
altitude” [1] before being termed CMS in 1998 [31].
CMS was then further divided into two subtypes: CMS
and high-altitude pulmonary hypertension [32]. However,
this division was confusing because CMS shares the same
term as one of its subtypes. It would be clearer to name
this subtype of CMS as characterized by excessive Hb
polycythemia, the original term.
CMS may manifest as high-altitude pulmonary edema
in about 1% of subjects with a low Hb concentration
[24], and these subjects could erroneously be classified
as having CMS using the scoring system for diagnosis.
Moreover, although CMS (polycythemia) is characterized
by excessive erythrocytosis, its importance is weakened
or “diluted” by multiple symptoms based on the present
diagnostic criteria. The weight of three points for excessive
polycythemia is lower than the weight of non-specific
symptoms, such as sleep disturbances, headache, and
dizziness, which can be found in a large number of
pathophysiologic conditions. Individuals with excessive
polycythemia, even those with very severe polycythemia,
may be missed, and the optimal treatment time before
the patient shows CMS symptoms may be missed. Based
on the above considerations, we suggest that Hb should
be given greater weight in the scoring system; for example,
6 points should be given for excessive polycythemia.
Impacts of height and length of residence at a high
altitude on CMS
We used binary logistic analysis to investigate the pre-
disposing factors for CMS. Among these factors, we
found that the altitude, length of residence at a high
altitude, alcohol use, and sO2 were significantly corre-
lated with the prevalence of CMS. We then analyzed the
impacts of height and length of residence at a high alti-
tude on CMS.
CMS usually occurs in long-term residents at a high
altitude of >3000 m. In one study, as the altitude in-
creased, the prevalence of CMS increased among Han
immigrants in the Qinghai-Tibet plateau (2,980–5,226 m)
[17]. However, our data followed this pattern only when
the altitude was ≥4500 m. The altitude was not associated
with the CMS prevalence or erythrocytosis at an altitude
of <4500 m. Thus, a significant number of humanscan become well acclimatized to hypoxic conditions
at <4500 m by maintaining a stable Hb concentration
(192.5 ± 17.2 g/L) below the “optimal” value (200 g/L)
irrespective of the altitude itself (Figure 2A,B). While
the altitude was ≥4500 m and the Hb concentration was
mostly ≥200 g/L (207.3 ± 21.8 g/L), excessive erythrocy-
tosis can trigger a vicious circle by impairing oxygen de-
livery and depressing cellular oxygen supplication. Thus,
4,500 m should be regarded as the threshold altitude for
dwelling, above which most humans cannot acclimatize to
such a high altitude.
CMS usually requires a specific duration of residence
to develop at a high altitude. A Han man can develop
CMS in <1 year at 5,300 m (2 months in the current
study), while others may not show obvious CMS symp-
toms until they have lived at a high altitude for ≥15 years
(30 years in this study) [17]. Some researchers are con-
vinced that the length of exposure to a high altitude is
not associated with the prevalence of CMS, whereas alti-
tude, sex, and ethnic background are significant factors
influencing the rate of CMS development [14]. Our data
definitely suggest that the length of residence at a high
altitude is significantly correlated with CMS develop-
ment, especially within the first 60 months because the
Hb concentration increases rapidly during this time
period. As a human being first ascends to high altitude,
the body immediately develops hypoxemia, which triggers
adaptive responses including hyperventilation, pulmonary
hypertension, and an increase in the cardiac output. As
time passes and chemosensitivity becomes blunted, the
above responses are substituted by erythrocytosis, angio-
genesis, and other processes. The erythrocyte and Hb
levels continue to increase to a very high point unless the
oxygen demand of the body is met. According to our data,
this mainly occurs within 60 months of living at a high
altitude. Thereafter, the rate of increase in the Hb con-
centration slows down significantly, and the CMS
prevalence gradually stabilizes. Therefore, medical ex-
aminations should be regularly performed within the
first 60 months of residing at a high altitude. Spending
the first 60 months at a high altitude without a CMS
incident ensures a much lower probability of the subse-
quent development of CMS.
Conclusions
The high prevalence of CMS evaluated in this study using
the latest approved scoring system [9] suggests that it is
more sensitive than previous diagnosis criteria and favors
early screening and treatment of patients with CMS. Based
on our data, we suggest that the Hb threshold for CMS is
200 g/L despite the altitude difference and that Hb is
weighted with >6 points in the CMS scoring system.
Moreover, an elevation of >4500 m and the first 60 months
after ascending are two critical factors associated with the
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medical examinations should be performed within
the first 60 months of residing at a high altitude, es-
pecially ≥4500 m, for early screening of CMS. To be
noticed, our study was focusing on younger subjects
(24.08 ± 5.66 years), which may limit the ability to
generalize and compare our results to other data sets.
More studies with larger population and from different
nations are needed to validate the above findings.
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